Hallucinogens

被引:860
作者
Nichols, DE [1 ]
机构
[1] Purdue Univ, Sch Pharm & Pharmacal Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
关键词
hallucinogen; 5-HT2A receptors; prefrontal cortex;
D O I
10.1016/j.pharmthera.2003.11.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes. They are considered physiologically safe and do not produce dependence or addiction. Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts. In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain. These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, especially those expressed on neocortical pyramidal cells. Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents. These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC). In vivo brain imaging in humans using [F-18]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metabolism, and correlations have been developed between activity in specific brain areas and psychological elements of the ASC produced by hallucinogens. The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research. In addition, it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:131 / 181
页数:51
相关论文
共 521 条
[1]   5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex [J].
Abi-Saab, WM ;
Bubser, M ;
Roth, RH ;
Deutch, AY .
NEUROPSYCHOPHARMACOLOGY, 1999, 20 (01) :92-96
[2]   The psychopharmacology of hallucinogens [J].
Abraham, HD ;
Aldridge, AM ;
Gogia, P .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (04) :285-298
[3]   Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors [J].
Acuña-Castillo, C ;
Villalobos, C ;
Moya, PR ;
Sáez, P ;
Cassels, BK ;
Huidobro-Toro, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (04) :510-519
[4]  
Aghajanian G. K., 1998, Society for Neuroscience Abstracts, V24, P1366
[5]   LYSERGIC ACID DIETHYLAMIDE - SENSITIVE NEURONAL UNITS IN MIDBRAIN RAPHE [J].
AGHAJANIAN, GK ;
FOOTE, WE ;
SHEARD, MH .
SCIENCE, 1968, 161 (3842) :706-+
[6]   Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release [J].
Aghajanian, GK ;
Marek, GJ .
BRAIN RESEARCH, 1999, 825 (1-2) :161-171
[7]   MESCALINE AND LSD FACILITATE THE ACTIVATION OF LOCUS COERULEUS NEURONS BY PERIPHERAL STIMULI [J].
AGHAJANIAN, GK .
BRAIN RESEARCH, 1980, 186 (02) :492-498
[8]  
Aghajanian GK, 1999, NEUROPSYCHOPHARMACOL, V21, pS16
[9]  
AGHAJANIAN GK, 1970, J PHARMACOL EXP THER, V171, P178
[10]  
AGHAJANIAN GK, 1964, CLIN PHARMACOL THER, V5, P611